Prothena (PRTA) “announced a scientific presentation at Neuroscience 2025, hosted by the Society for Neuroscience in San Diego, CA. CYTOPE is a novel drug delivery modality enabling cytosolic delivery of macromolecules in the brain and periphery through an efficient endosomal escape mechanism that preserves membrane and vesicle integrity following systemic administration. This technology potentially allows for targeting of previously undruggable intracellular disease targets. To demonstrate this, we developed and investigated our TDP-43 CYTOPE program in multiple preclinical models.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena’s Coramitug: Promising Phase 2 Results and Buy Rating for ATTR-CM Advancements
- Prothena highlights positive Phase 2 Coramitug data published in AHA journal
- Prothena price target raised to $30 from $20 at H.C. Wainwright
- Prothena Corporation’s Q3 2025 Financial and Clinical Updates
- Prothena reports Q3 EPS (68c), consensus (54c)